Case Studies

BACKGROUND Verrica Pharmaceuticals has been a LifeSci client since December 2022. As part of the strategy to raise the Company’s visibility amongst global investors, LifeSci scheduled multiple Non-Deal Roadshows with top-tier institutions as well as organized and hosted an in-person High-Net-Worth and family-office investor event for Verrica in New York City. The event created a…

BACKGROUND AlphaTau has been a LifeSci client since July 2021. As part of a strategy to raise visibility amongst investors, LifeSci organized over 60 virtual and in-person Non-Deal Roadshows since joining forces as well as hosting an in-person High-Net-Worth Group Event with over 73 meeting attendees. LIFESCI’S ACTIVITIES • Continuous proactive outreach to new investors,…

BACKGROUND Femasys Inc. has been a LifeSci client since July 2021. As part of a strategy to raise the Company’s visibility amongst global investors, LifeSci organized and hosted an in-person High-Net-Worth and family-office investor event for Femasys in New York City. The event created a great opportunity for Femasys to showcase its first-in-class technologies in…

InspireMD successfully completed a transformational Private Placement for up to $113.6 million, with $42.2 million financing upfront with up to an additional $71.4 million tied to exercise of milestone-driven warrants. LIFESCI’s ACTIVITIES Continuous efforts to strengthen company relationships with relevant sell-side analysts to improve research coverage through leveraging existing relationships and making new introductions to…

Orchestra BioMed’s partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products it develops. LIFESCI’s ACTIVITIES LifeSci engaged following a global strategic partnership with Terumo announced in June 2019 Strengthen the equity story and position the Company to secure additional strategic global partnerships Raise visibility…

LifeSci have worked extensively over the years to raise the Company’s visibility amongst investors and strategics, preparing the market for their positive data read out and ultimately leading to a successful acquisition. LIFESCI’s ACTIVITIES Strengthen Amryt’s position as a global leader in rare and orphan diseases through strategic corporate communications following the acquisition of Chiasma…

BACKGROUND Bellus Health is a clinical-stage biopharmaceutical company focused on developing a P2X3 antagonist to address refractory chronic cough and other hypersensitization disorders. The Company’s lead candidate, BLU-5937, is a highly selective P2X3 antagonist currently being developed for the treatment of refractory chronic cough. LifeSci Advisors has been engaged to support Bellus Health with investor…

LIFESCI’s ACTIVITIES Aggressive outreach to new investors and sell-side analysts Arranged 80 TTW and IPO roadshow meetings Arranged 13 meetings during the 2022 LifeSci Corporate Access Event Worked with management to strengthen messaging and optimize competitive positioning for MAU868 and other pipeline programs Organized two well-attended KOL events for ‘Ataciept’ and ‘MAU868’. Provided capital markets…